-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Two anaerobic protozoa, human Bifidobacteria Blastocystis hominis (B. hominis) and the vulnerability chycosma Ditmoeba fragilis (D. Fragilis) is considered a "neglected parasite" that is common in the human gut.
in many low-income countries, poverty and poor sanitation are the main causes of transmission.
two parasites are usually transmitted through fecal-oral contact or water/food contamination, with gastrointestinal symptoms similar to intestinal irritable syndrome (IBS) and inflammatory bowel disease (IBD).
Methazole was first used as an oral antibiotic in 1962 for the treatment of trictomosomy, and in a study that treated D. fragilis with methazole or tetramine, a therapeutic response was observed in 60 per cent of patients, with symptoms in 30 per cent of patients treated with methazole alone, while tetrin was ineffective.
, the study aims to explore the therapeutic effects of triple antibiotic therapy using enema infusions in human Bifidobacteria and vulnerability to chelogenic infections.
This is a retrospective longitudinal study that treated 54 patients (over the age of 18) who were positive for human Bifidobacteria and libido infections with rectal tri-antibiotics for two consecutive days.
stool samples from participants before and after treatment and used microscopes and polymerase chain reactions to detect their parasites.
to record the patient's symptoms and the patient's demographics before and after treatment.
all patients were human Bifidobacteria (37 per cent) infected or vulnerable Vibrio-positive (35 per cent) or both (28 per cent).
all patients completed two days of treatment and no serious adverse reactions were reported.
most common side effects experienced by patients during treatment are color changes in urine.
common symptoms reported before treatment are diarrhea, abdominal pain, constipation and fatigue.
other symptoms include abdominal discomfort, dizziness and stool blood.
89% of patients completed the final stool test after treatment.
six weeks after treatment, 79 percent of patients removed parasites from their faeces.
7 days and 6 weeks after treatment, symptoms such as abdominal discomfort, dizziness and stool blood decreased significantly .
no significant effect on the eradication of parasites through the retention of the enema, intestinal preparation, previous antibiotic treatment or previous gastrointestinal problems.
overall, the eradication of parasites and improvements in clinical outcomes were observed in patients treated with two-day enema antibiotics, demonstrating that this treatment can eradicate parasites and improve clinical outcomes.
.